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Chapter I 
 
Hemozoin: Crystal Engineering Survivability 
(Chapter I taken from Hemozoin: Crystal Engineering Survivability, published in the 
Encyclopedia of inorganic and Bioinorganic Chemistry, 2012) 
 
 
Introduction 
In nature, biomineralization is observed across the entire biosphere.  These biologically 
synthesized materials can consist of carbonate, phosphate, oxalate, silica, iron, go2ld 
and many other diverse compositions of organic or inorganic materials.  The most well-
known examples of biomineralization are those that lend structural support to a species, 
including the formation of bones in vertebrates and the shells of eggs.  Magnetotactic 
bacteria also rely on the formation of magnetic nanometer-size Fe3O2 crystallites in 
order to locate oxygen-rich environments by sensing the Earth’s geomagnetic field.  The 
formation of these biominerals generally occurs under physiological conditions in a 
highly controlled and organized sequence of events.  Another biomineral, hemozoin, is a 
heme crystal synthesized by the malaria parasite as a survival mechanism to escape 
heme related toxicity.  The discovery of this detoxification biomineral actually precedes 
the discovery of the malaria parasite itself.  Although hemozoin has been studied since 
the 18th century, scientists have only begun to obtain a detailed understanding of the 
structure and formation of this biomineral in the last twenty five years.  Hemozoin 
2 
 
formation is an important drug target in antimalarial drug discovery and development.  
In fact, the most successful antimalarial developed to date, chloroquine, acts by 
disrupting formation of hemozoin.  Unfortunately, chloroquine is now ineffective as an 
antimalarial due to the emergence 2of multidrug-resistant strains of the parasite, 
though hemozoin remains a viable drug target in antimalarial drug discovery.  In order 
to develop new antimalarial compounds that target the formation of hemozoin, it is 
important to have a sound understanding of the formation of this biocrystal. 
 
Homeostasis of Heme 
 The internal environment of all biological systems must be carefully regulated.  
The heme molecule is a perfect example of the importance of this homeostasis. Heme is 
essential to aerobic organisms, playing important roles in many biological reactions such 
as oxygen transport, respiration, drug detoxification and signal transduction (1-4).  
However, when heme is released in an uncontrolled fashion into a living organism it can 
become extremely toxic.  One example demonstrating the toxic effects of heme is seen 
in rhabdomylosis.  Here, trauma or injury results in the rapid breakdown of muscle 
tissue, releasing myoglobin into the bloodstream.  This harmful heme-containing protein 
is not normally found in blood. In the kidney, heme exposure promotes oxidative stress 
in renal cells by increasing lipid peroxidation, and can cause local inflammatory 
reactions ultimately leading to renal failure (5, 6). The ability of heme to promote 
oxidative stress can be attributed to the presence of the redox-active iron center that 
can generate reactive oxygen species (ROS), leading to damage to lipids, proteins, and 
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DNA.  Free heme has also been shown to interact with proteins, catalyzing the 
degradation of proteins into small peptide fragments and causing covalent cross-linking 
of Apolipoprotein B, triggering atherosclerosis (7).  Studies have also shown that 
exposure to heme results in nicking and degradation of DNA.  The mtDNA of liver cells 
shows that the large region that codes for cytochrome c oxidase and NADH 
dehydrogenase is deleted in cells exposed to hemin. This mtDNA damage leads to the 
altered expression of mitochondrial cell death proteins, suggesting a role of hemin in 
influencing apoptosis (8).  
 
Detoxification of Heme in Humans 
As protection against the drastic toxic effects of free heme, humans are 
equipped with several detoxification mechanisms.  Primarily, heme detoxification is 
carried out by the heme oxygenase (HO) systems (HO-1, HO-2 and HO-3), and by extra-
HO systems less frequently, including hemopexin and albumin (9). These HO enzymes 
play a large role in protecting cells from the oxidative stress caused by free heme by 
working with NADPH–cytochrome P450 to break down the porphyrin ring into 
equimolar amounts of free iron, biliverdin, and carbon monoxide (10).  In this process, 
HO transfers reducing equivalents to the α-methene bridge of heme from NADPH-
cytochrome P-450 reductase to open the tetra-pyrrolic ring, freeing CO and biliverdin.  
Biliverdin is then converted to bilirubin by biliverdin reductase, conjugated to glucuronic 
acid, and excreted from the body (Figure 1) (11, 12). The HO systems are very efficient 
at detoxifying free heme and restoring homeostasis in the organisms that have them, 
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but organisms that lack the HO systems have developed alternative mechanisms to 
protect themselves from free heme toxicity. 
 
 
 
 
 
 
Figure 1. Pathway of free heme detoxification by Heme 
Oxygenase. 
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Heme Detoxification in the Malaria Parasite 
One organism lacking a HO system is the parasite responsible for malaria.  
Malaria is caused by several species of intracellular parasites of the Plasmodium genus.  
Of this genus, there have been at least 200 species identified, with P. falciparum being 
the primary causative agent of human malaria.  The lifecycle of the malaria parasite is 
quite complex (Figure 2).  P. falciparum sporozoites are transmitted to humans through 
the saliva of a female Anopheles mosquito during a blood meal.  Once in the host’s 
bloodstream, P. falciparum sporozites invade the hepatocytes and undergo a phase of 
growth and differentiation followed by the release of merozoites into the bloodstream.  
The merozoites then enter host red blood cells, referred to as the the intraerythrocytic 
stage of infection. This stage is characterized by the onset of the symptoms of a malaria 
infection. Inside the erythrocyte, the parasite goes through three distinct growth phases 
that can be distinguished under a light microscope. The ring stage is first, lasting about 
24 hours. The second stage is the very active trophozoite stage. It is during this stage 
that most of the erythrocyte cytoplasm is consumed. Third , the parasite undergoes 4-5 
cycles of binary divisions, producing merozoites that eventually rupture the red blood 
cell membrane, and enter the bloodstream to infect new red blood cells (13). During 
this intraerythrocytic cycle, the host cytoplasm is consumed, and an estimated 60-80% 
of available hemoglobin is degraded for use as a nutrient source (14).  During this 
degradation process, the amino acids obtained from hemoglobin catabolism are 
incorporated into P. falciparum proteins and used for energy metabolism (15) (16-18).  
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The amino acids P. falciparum cannot obtain from hemoglobin are readily scavenged 
from the environment (19, 20). 
 
 
 
 
 
 
 
The malaria parasite obtains hemoglobin from the cytosol through invagination 
of the parasitophorous vacuolar and plasma membrane, creating a double membrane 
vesicle. These vesicles fuse together, creating a single membrane digestive food vacuole.  
Figure 2. Life-cycle of Plasmodium falciparum 
in the human host. 
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Once formed, the digestive food vacuole becomes the primary site of hemoglobin 
digestion (21, 22). This specialized organelle maintains an acidic environment, estimated 
pH of 4.8 (19, 23). Inside this organelle, aspartic and cysteine protease activities have 
been detected that are the primary enzymes responsible for globin proteolysis.  Aspartic 
proteases make up about 60-80% of enzyme activity, while cysteine proteases make up 
20-40% (24, 25). The process of hemoglobin degradation has been found to occur in a 
specific order, requiring an initial aspartic protease cleavage, followed by secondary 
aspartic protease and cysteine protease cleavages (26). Vacuolar degradation produces 
small polypeptides, but no free amino acids. This suggests that cleavage of the small 
peptide fragments occurs in the cytoplasm, outside of the digestive vacuole (26-28).  
Sequencing of the P. falciparum genome has found at least ten genes encoding 
aspartic proteases, plasmepsins I, II, IV-X, and histo-aspartic protease (HAP) (26, 28).  
HAP is 60% homologous to plasmepsins I and II, but has several substitutions, one of 
which is the replacement of the catalytic aspartate with a histidine (29). Of the ten 
genes that encode plasmepsins in P. falciparum, three are not expressed in 
intraerythrocytic growth stages (plasmepsins VI, VII, and VIII), and three are expressed, 
but do not seem to be active in the digestive food vacuole (plasmepsins V, IX, and X).  
Plasmepsins I, II, IV, and HAP are the only aspartic proteases that are found in the 
digestive food vacuole, and participate in hemoglobin degradation.  Plasmepsin I has 
been shown to cleave hemoglobin between α33Phe-34Leu with exceptional specificity 
(30). This is significant because the α33-34 bond is in the hinge region of the hemoglobin 
molecule.  This region is responsible for holding the protein together when oxygen is 
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bound.  Cleaving this domain unravels the heme molecule, exposing other amino acid 
residues for cleavage by the secondary proteases (31). Plasmepsins II and IV have been 
shown to cleave native hemoglobin, but prefer to cleave already denatured hemoglobin 
indicating that they function primarily as secondary proteases (28, 32, 33).  HAP is a 
secondary protease, showing less efficiency in cleaving the α33-34 bond of native 
hemoglobin, although it is a full order of magnitude faster than the other plasmepsins at 
cleaving denatured globin at other sites (28, 32, 34).  
The P. falciparum genome encodes four falcipains; falcipain I, II, II’ and falcipain 
III (28, 33, 35). Falcipain I has not been shown to be involved in hemoglobin 
degradation, but falcipains II and III have acidic optimal pH, and are localized in the 
digestive food vacuole, indicating their involvement in hemoglobin digestion (33). Both 
falcipain II and III are capable of hydrolyzing native and denatured hemoglobin, but 
falcipain II has been shown to be more active against peptidyl substrates compared to 
falcipain III (36-38).  
Finally, a metalloprotease, falcilysin, also participates in the hemoglobin 
degradation pathway. Falcilysin is a member of the M16 family of the clan ME zinc 
metalloproteases.  This family of metalloproteases is characterized by an inverted active 
site motif of HXXEH. The two histidine residues and glutamate residues C-terminal to 
this motif are involved in coordinating a catalytic zinc ion (37, 38).  Falcilysin is unable to 
cleave native hemoglobin or denatured globin, instead preferring to cleave small globin 
peptides up to 20 amino acids in length (39). It appears that falcilysin acts as a 
complement to the plasmepsins and falcipains, acting downstream, and cleaving 
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preferentially at polar residues, while plasmepsins and falcipains cleave at hydrophobic 
residues (40). The cleavage of globin peptides by facilysin is essential for production of 
peptides small enough to be transported to the cytosol of the parasite for further 
cleavage to amino acids, signifying the end of hemoglobin degradation in the digestive 
food vacuole.  
 During this process of hemoglobin degradation, large quantities of free heme are 
released and can reach concentrations of 400 mM if heme detoxification is prevented 
(40). The presence of free heme within the digestive food vacuole has several 
undesirable consequences.  Heme concentrations as low as 10-20 µM have been shown 
to inhibit several proteases present within the digestive food vacuole including the 
plasmepsins and falcipains (40).  In addition to inhibiting enzymatic activity, the 
presence of free heme is detrimental to the stability and deformability of the parasite 
vacuolar membrane (15).  The resulting hemolysis is likely caused by perturbations to 
the membrane structure from the insertion of lipophilic heme into the phospholipid 
bilayer.  A further consequence of free heme accumulation is the increase in oxidative 
stress on the parasite (41). Since the malaria parasite does not have HO like vertebrates, 
the parasite detoxifies free heme by converting soluble, toxic free heme into an 
insoluble, nontoxic crystal called hemozoin.  This process is essential to parasite survival, 
as inhibition of hemozoin formation results in parasite death (42).  Indeed, the most 
successful antimalarial ever developed, chloroquine, has been shown to inhibit this 
detoxification pathway supposedly by binding free heme and preventing its insertion 
into the growing hemozoin crystal.  Unfortunately, due to resistance mechanisms 
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developed by the parasite, chloroquine no longer has clinical efficacy.  However, 
hemozoin remains a valid drug target as resistance is a result of efflux, and resistant 
strains of the parasite still produce hemozoin normally.  Therefore, it is essential that 
the formation of this biocrystal is better understood in order to promote the discovery 
of new antimalarials that target hemozoin formation. 
 
The Structure of Hemozoin 
 Lancisi reported the discovery of hemozoin, the dark brown-black malarial 
pigment, in 1717 (43). As these deposits are quite pronounced in the brains, spleens and 
livers of malaria victims, the discovery of hemozoin actually precedes the discovery of 
the malaria parasite itself by over 150 years.  For many years, it was hotly contested as 
to whether or not pigment was the actual cause of malaria, but in 1890, Golgi presented 
a photograph of a pigmented parasite in the blood of a malaria patient, forging the 
connection between hemozoin and malaria (15, 44). The composition and structure of 
hemozoin remained a subject of intense debate until 2000 when X-ray powder 
diffraction methods were used to identify the structure of β-hematin, the synthetic 
equivalent of hemozoin (45). Once thought to consist of polymeric strands of O-Fe(III) 
linked heme units, XRD revealed a centrosymmetric triclinic unit cell comprised of 
reciprocal head-to-tail dimeric units of heme bound through propionate O-Fe(III) with a 
bond distance of 1.866(2) Å (Figure 3).  The propionic acid groups of the heme dimer 
then hydrogen bond with other dimers to form the extended crystal.  Morphologically, 
β-hematin and hemozoin crystals are needle-like and exhibit dominant, slow growing 
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{100} and {010} side faces with minor, less pronounced fast growing {011} and (46) end 
faces (Figure 4).  This morphology is conserved among various species of Plasmodium 
(Figure 5).    
 
 
 
 
 
 
 
 
 
Figure 3. Structure of Hemozoin 
Figure 4. Crystal morphology of hemozoin showing 
slow-growing {100} and {010} side faces, and fast-
growing {011} and {46} faces. 
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 Hemozoin and β-hematin are equivalent   
Understanding the mechanism by which the parasite converts soluble, toxic free 
heme into an insoluble and non-toxic crystal is valuable for antimalarial drug-discovery, 
as perturbations to this crystallization process can result in parasite death.  However, 
Figure 5. Electron micrographs show the heterogeneity of shape and size 
for B-hematin and hemozoin. Images of B-hematin (a) compared to that 
of hemozoin from P. falciparum clones Dd2 (b1) and 3B-D5 (b2), and 
hemozoin from P. Vivax (c), P. ovale (d), and P. malariae (e). The size bar 
is 200 nm (50). 
13 
 
studying the formation of hemozoin in vivo has proven challenging to researchers. β-
hematin (BH), the abiological version, has been utilized as a tool to study hemozoin 
formation in vitro.  For such comparisons to be meaningful, it had to be unequivocally 
established that these entities are isostructural.  Chemical, spectroscopic, and 
crystallographic evidence have been used to conclude the similarity of these two 
materials.   
Chemically, both hemozoin and BH are composed of insoluble, head-to-tail 
dimers of Fe(III)PPIX (47). Spectroscopically, the similarity of hemozoin and BH dimeric 
units can be confirmed from the infrared spectrum, that exhibits fingerprint vibrations 
around 1664 and 1211 cm-1 corresponding to the C=O and C-O stretching from 
coordination of the propionate O atom to the Fe(III) metal center of the neighboring 
heme molecule (48). Furthermore, the Fe(III) spin state of each species is identical, 
confirmed by variable temperature EPR that has shown that both BH and hemozoin 
exist in the high spin S=5/2 state, a paramagnetic complex.  This observation is in 
agreement with Mӧssbauer data where the isomer shift and quadrupolar splitting 
values suggest that the Fe(III) exists in a high-spin state (47, 49). Morphologically, SEM 
images reveal that both BH and hemozoin are composed of needle-like crystals with 
tapered habits (Figure 5A and 5B). The crystal structure of each species is nearly 
identical. Synchrotron x-ray powder diffraction patterns have demonstrated that the 
crystal structure of hemozoin is identical to its synthetic counterpart (50).  However, a 
more recent study suggests hemozoin may contain slightly more disorder in the Fe-O 
bonds than BH formed under nonaqueous equilibrium conditions (51).  
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Mechanism of Hemozoin Formation 
 The conversion of free heme to BH does not occur at a physiologically relevant 
rate in aqueous solution, suggesting that the in vivo formation of hemozoin within the 
digestive food vacuole of the parasite requires the presence of a biological mediator.  
While the precise mechanism by which hemozoin formation occurs in vivo is not fully 
elucidated, recent studies strongly support the hypothesis that neutral lipid bodies are 
the biological template for hemozoin crystallization.  In support of this hypothesis, 
several synthetic routes for BH formation have been described demonstrating that 
neutral lipid bodies serve as both a protective reservoir for free heme and a kinetically 
competent site for crystallization.   
 
Biological formation of Hemozoin 
 Until recently, identification of the biological mediator responsible for hemozoin 
formation was a controversial topic, as proteins, membrane lipids and neutral lipids 
extracted from the Plasmodium parasite were each shown to mediate BH formation in 
vitro.  Indeed, many biological components within parasite lysates are quite capable of 
promoting the formation of BH in vitro.  One of the earliest studies of these lysates was 
conducted by Slater and Cerami who examined trophozoite extracts (52). The formation 
of BH in the presence of these extracts was dependent on pH, time and concentration.  
Furthermore, several quinoline-antimalarials (known to inhibit the formation of 
hemozoin in vivo) were found to inhibit the process of BH formation in the presence of 
these lysates.  The authors concluded that the presence of an enzyme, a heme 
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polymerase, was responsible for mediating the formation of BH, as activity of these 
lysates was sensitive to both heat and treatment with 1% SDS.  However, subsequent 
work contradicted this hypothesis, demonstrating that heat treated parasite lysates 
retained activity and therefore are not dependent on the presence of an enzyme (49).  It 
was suggested that BH formation in these experiments was actually due to the presence 
of hemozoin crystals within the lysates.  In fact, the authors showed that preformed BH 
crystals were sufficient to seed the process of crystallization in vitro.  While these 
studies demonstrated that an enzyme is not necessary for hemozoin formation, the 
mechanism of hemozoin crystallization remained unanswered.  
Polar membrane lipids were also implicated as a possible mediator of hemozoin 
formation.  Bendrat et al. first implicated these polar lipids when acetonitrile extracts of 
authentic hemozoin were found to promote the formation of BH (53). MS analysis of 
these extracts identified the presence of the methyl esters of oleic, palmitic and stearic 
acids and low yields of phospholipids within the active fractions.  Further, it seemed that 
these studies were in agreement with a previously published TEM image of an intact 
parasite showing aligned parallelepiped crystals of hemozoin present within the DV of 
the parasite (54).  These observations supported the hypothesis that crystallization 
occurs via epitaxial nucleation of hemozoin at the lipid layer of the vacuolar membrane 
(55).  Despite the strength of this argument, it was later revealed that axenic parasite 
cultures lacking a parasitophorus vacuolar membrane still produce hemozoin, ruling out 
any role for these membrane lipids in the parasite’s mechanism of heme detoxification 
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(56). While these polar membrane lipids are capable of promoting BH formation in vitro, 
they are not responsible for the in vivo formation of hemozoin. 
Though polar membrane lipids were ruled out as the mediator of hemozoin 
formation, additional studies by Dorn et al. showed that extracts from uninfected 
erythrocytes as well as several types of phospholipids are also capable of promoting the 
formation of BH (56, 57). These observations suggest that a hydrophobic environment is 
ideal for promoting formation of BH.  Several in vitro studies substantiate this 
hypothesis by probing both the rate and activation barrier of BH formation in the 
presence of several types of solvents, alcohols and acids with varying degrees of 
hydrophobicity (58). Several acids, including benzoic and acetic acid have been shown to 
mediate BH formation (59).  The ability of the acid to promote BH formation increases 
as a function of concentration.  It has been suggested that this concentration 
dependence is due to an increase in heme solubility, the limiting step in BH formation.  
This observation would explain the abundance of active BH mediators obtained from 
lipophilic biological extracts.  As heme itself is quite hydrophobic and insoluble in 
aqueous solution, it would be expected that heme solubility would increase of a 
function of increasing hydrophobicity of the surrounding environment.   
Following this line of thinking, aromatic and aliphatic alcohol-water mixtures of 
varying hydrophobicity have been studied for their ability to promote BH crystallization 
(60-62). In one such study, the ability of several small normal and structurally similar 
alcohols with varying degrees of hydrophobicity were investigated (61). The results 
indicate that activity follows the trend of butanol > propanol > ethanol > methanol.  
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These data suggest that the hydrophobicity of the alcohol is directly related to its 
potency as a mediator of BH formation.  The authors further investigated the 
solubilization of heme in the presence of the alcohols and found an exponential increase 
of heme solubility is observed as a function of increasing alcohol concentration.  
Further, the ability of an alcohol to solubilize free heme followed the trend of proponal 
> ethanol > methanol indicating that the hydrophobicity of the alcohol increases the 
solubility of heme.  These data would support the concept of an in vivo mediator of 
hemozoin formation that is hydrophobic in nature and acts to solubilize free heme. 
In vitro experiments have shown that BH formation occurs efficiently at the 
surface of a hydrophilic/hydrophobic interfacial region.  These observations were made 
using aqueous/alcohol mixtures in the presence or absence of an interfacial region (63, 
64). To study the effects of this interfacial region, a cosolvent system was implemented 
where a 9:1 solution of methanol:alcohol was used.  In the case of 1-octanol, 1-hexanol 
and 1-pentanol, the first two solvents are biphasic in aqueous medium, while the latter 
exhibits a single phase in aqueous solution.  The rates of formation of BH at 
physiological temperature and digestive food vacuole pH for the solvent systems are 7-9 
minutes for the biphasic solutions, but 110 minutes for the 1-pentanol solution, which 
could suggest that the presence of an interfacial region is important.  To confirm the 
importance of this lipophilic interface, a solution of 6:4 methanol:pentanol or octanol 
was used, so as to induce an interfacial region in the pentanol solution.  The results 
show that the 1-octanol solution has a similar half-life (12 min) as observed in the 9:1 
solution (7.1 min).  However, the 1-pentanol solution with an interfacial region shows a 
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half-life of 10 min, as compared to the kinetics in the absence of an interface where the 
half-life is 110 min.  Another study with resonance raman spectroscopy using an 
immersion probe confirmed that the formation of BH occurs within 1 µm of a 
pentanol/water interface.  Due to the dependence of BH formation on the presence of 
an interfacial region, perhaps formation of hemozoin at a lipid/aqueous interface 
explains the alignment of crystals on neutral lipid bodies observed in TEM images.   
 These in vitro experiments demonstrate that hydrophobic interactions are 
important in free heme detoxification, suggesting that a lipophilic source present within 
the digestive food vacuole is responsible for mediating hemozoin formation.  Since polar 
membrane lipids have been previously ruled out, is there another possible lipophilic 
source present at the site of hemozoin formation?  With the identification of neutral 
lipids bodies present within the digestive food vacuole, the focus shifted to these 
neutral lipids as the possible site of hemozoin formation.  
 
Implication of Neutral Lipids in Hemozoin Formation 
During infection with P. falciparum, there is a six-fold increase of lipid content 
within the erythrocyte for the support of growth and differentiation of the parasite.  
While the parasite does support limited synthesis of short chain fatty acids, the lipid 
content of the growing parasite is mostly scavenged from the host.  During this process, 
there is a significant increase in triacylglycerol content, a neutral lipid that is only 
detected in small amounts within an uninfected erythrocyte.  Within the digestive food 
vacuole of the parasite, aggregates of these neutral lipids are observed.  Confocal 
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images reveal these lipid bodies are a few hundred nm in diameter and determined to 
consist of a mixture of di- and triacylglycerols (neutral lipids) (64). Based on previous 
knowledge that mono- di- and triacylglycerols are capable of promoting BH formation, it 
was proposed that the neutral lipid bodies serve as a mediating template for the 
formation of hemozoin (48).  Later, Sullivan and coworkers revealed a TEM image clearly 
showing crystals of hemozoin aligned along the surface of these lipid bodies, thereby 
strengthening the role of these hydrophobic bodies in hemozoin formation (Figure 6) 
(65). 
 
 
 
 
 
Figure 6. (a) hemozoin formation within lipid droplets is observed with 
malachite green fixation. (b) Formation of hemozoin crystals within a lipid 
droplet. Seen with malachite green fixation (65). 
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  In an attempt to identify the specific composition of these neutral lipid bodies, 
the authors extracted the digestive food vacuole of the parasite and performed lipid 
analysis using ESI-MS/MS (electrospray ionization tandem MS) on the hemozoin 
extracts.  The results showed that the lipid composition surrounding the hemozoin 
crystals are composed of a specific ratio of neutral lipids in an approximate ratio of 
4:2:1:1:1 of MSG (monostearic glycerol), MPG (monopalmitic glycerol), DPG (dipalmitic 
glycerol), DOG (dioleic glycerol) and DLG (dilinoleic glycerol).  The authors investigated 
the kinetic formation of BH in the presence of this blend of neutral lipids and revealed 
that BH crystallization occurred within ten minutes of incubation with linear growth for 
2 h before reaching 80% product conversion.  The authors also provided evidence that 
the neutral lipid bodies help protect heme from peroxide degradation, which would lead 
to parasite toxicity.  In the absence of these lipids, a 50 mM H2O2 solution degraded 50% 
of dilipidated hemozoin, while a 90 mM concentration of peroxide was necessary to 
reduce encapsulated hemozoin by 50%, suggesting that the lipids may also serve as a 
protective reservoir for free heme preceding its incorporation into the nontoxic 
hemozoin crystal. 
 
Localization of free heme in the neutral lipid body 
This interpretation of the lipid body serving as a reservoir for free heme is 
supported by in vitro confocal evidence (66).  Fluorescently labeled synthetic neutral 
lipid bodies (SNLDs) were generated by dissolving the biological blend of neutral lipids in 
1:9 acetone:methanol in the presence of Nile Red.  When added to a pH 4.8 citric buffer, 
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the hydrophobic lipids minimize interactions with water by forming spherical, 
continuous hydrophobic bodies, very similar to those observed within the native 
environment of the parasitic digestive food vacuole.  As these SNLDs are formed, Nile 
Red becomes trapped within the hydrophobic environment, and any Nile Red not 
enveloped within the SNLDs will be quenched by water.  The resultant fluorescent 
SNLDs can be visualized using confocal microscopy (Figure 7).  This system was then 
titrated with heme, which quenches Nile Red in a concentration dependent manner.  At 
pH 4.8, it is observed that free heme rapidly partitions throughout the lipid body from 
the outside-in.  Complete quenching is observed in 200 seconds.  However, at pH 1.3 
and 7.3, quenching is much slower and appears to associate with the near surface layer 
of lipids (Figure 8a).  The partitioning of free heme as a function of pH follows a bell-
shaped curve, with maximal heme partitioning observed at digestive food vacuole pH 
4.8.  Importantly, the pH dependence of the yield of BH formation follows the same 
trend, indicating that BH formation occurs as a function of heme partitioning into the 
SNLDs (Figure 8b).  
 
 
 
Figure 7. (a) Confocal microscopy images showing neutral lipid droplets containing Nile 
Red. (b) As the droplets were titrated with heme, the Nile Red fluorescence was 
quenched, indicating that free heme partitions into neutral lipid bodies. 
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Kinetically competent site for BH formation 
It has been estimated that the maximum half-life required for hemozoin 
conversion must be no more than 40 minutes in order for the parasite to escape free 
heme toxicity (67).  If the neutral lipid body is imagined to be a reservoir for toxic heme, 
then it must be capable of promoting the formation of hemozoin at a kinetically 
Figure 8. (a) Comparison of Nile Red quenching as a function 
of time at different pH. (b) Partitioning of free heme as a 
function of pH follows a bell-shaped curve, with maximum 
partitioning occurring at 4.8. 
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competent rate.  Recently, an in vitro study that mimics digestive food vacuole 
conditions has established the ability of these SNLDs to mediate the formation of BH 
(68, 69).  SNLDs were created in a pH 4.8 citric acid buffer at 37⁰C.  An aliquot of 
Fe(III)PPIX was then added to the SNLDs in order to determine the half-life of BH 
formation.  The product obtained was then crystallographically verified to be equivalent 
to hemozoin.  In the biologically relevant 4:2:1:1:1 ratio SNLDs, the half-life of BH 
formation was 1.9 ± 0.01 min, demonstrating that the neutral lipid blend is capable of 
successfully detoxifying free heme at a physiologically realistic rate that would protect 
the parasite from toxicity. 
 
 Significance of the blend of neutral lipids     
 Based on the wealth of data that supports BH formation in a lipophilic 
environment, it is not surprising that these neutral lipid bodies would be the in vivo 
location of hemozoin formation.  It is interesting, however, that the parasite uses the 
specific blend of mono- and di-acylglycerols in the 4:2:1:1:1 ratio.  Does this unique 
blend of neutral lipids offer an advantage over utilizing individual lipid components?  To 
probe this question, temperature dependent kinetic measurements have been 
undertaken to determine whether the neutral lipid blend offers a lower activation 
barrier for BH formation over the individual lipid components (70, 71).  For these 
experiments, SNLDs of each individual lipid component and the biological mixture (100 
μM) were synthesized followed by the addition of Fe(III)PPIX.  Kinetic observations were 
made to determine the half-life of BH formation as a function of time (Figure 9b).  The 
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resulting data was fit to the Arrhenius equation and the activation energy was 
determined (Figure 9c). The activation barriers for MSG, MPG, DOG, DLG, and DPG were 
74.8 ± 5.3, 60.4 ± 7.1, 37.7 ± 3.3, 44.5 ± 15.4 and 35.2 ± 9.4 kJ/mol, respectively.  These 
results show that the monoglycerides exhibit an energy barrier that is higher than 
observed for the diglycerides.  However, in the neutral lipid blend (final concentration 
100 µM) the activation barrier is 27.8 ± 3.4 kJ/mol (Figure 9a), lower than that of any of 
the individual lipid components.   
 
 
 
 
 
Figure 9. (a) Activation energy of neutral lipid blend, and separate mono-, di-
glycerides. (b) half-life of BH formation as a function of time. (c) Activation energy 
was determined by the Arrhenius Equation. 
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This lower activation barrier suggests that the lipid blend offers an advantage compared 
to using an individual lipid component.  Recognizing this difference, Hoang et al. further 
examined these lipids to identify whether or not the lipid blend exhibited properties 
that are unique from the individual lipid components.  Using differential scanning 
calorimetry (DSC), a thermoanalytical technique that detects phase transitions by 
measuring the heat flux of a sample, it was discovered that new intermolecular 
interactions are observed in the lipid blend that are not present within the individual 
components, demonstrating that the blend has a different molecular organization than 
the individual components.  
 
Molecular Dynamics Simulations 
In addition to experimental data that suggests hemozoin formation occurs in the 
presence of neutral lipid bodies, molecular dynamics (MD) simulations have further 
shown that crystallization would be supported in this lipophilic environment (67-69).  In 
MD in vacuum, the interaction of two H2O-Fe(III)PPIX molecules form a precursor to the 
head to tail dimer (Figure 10) in which the propionate groups interact with the 
corresponding Fe(III) center.  A ligand exchange then occurs with the displacement of 
the water ligand from the axial position of Fe(III) and formation of the Fe-O bond.  Rapid 
hydrogen bonding between the propionic groups of dimers then occur.  In these 
simulations, if water molecules are present with the precursor dimer, the propionate 
groups move away from the Fe(III) center to interact with the water molecules.  These 
simulations would suggest that the neutral lipid body serves as a hydrophobic 
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environment that minimizes the interactions with water molecules and drives formation 
of the hemozoin crystal.   
 
 
 
 
 
 
 No single piece of evidence presented here alone could unequivocally implicate 
neutral lipids in heme detoxification in vivo.  However, collectively, a role for neutral 
lipid bodies in hemozoin formation is undeniable.  Not only has confocal evidence 
shown that heme spontaneously localizes within these neutral lipid bodies, but they also 
serve as a kinetically competent site for hemozoin formation.  Previous evidence 
showing hemozoin encapsulated within these neutral lipid bodies provides convincing 
evidence that this is indeed the site for hemozoin formation within the digestive food 
vacuole.  MD studies further substantiate the likelihood that hemozoin formation occurs 
at this site.  It is clear that free heme accumulates within the neutral lipid body, and that 
the lipid bodies are sufficient to quickly detoxify free heme on a physiologically relevant 
time scale.  The rapid formation of the head-to-tail dimer is favored in the lipophilic 
Figure 10. Molecular Dynamics (MD) simulation of 
hemozoin formation 
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environment and would not be expected to occur rapidly in aqueous solution due to 
competitive hydrogen bonding.   
 
Antimalarials 
 The malaria parasite contains several unique metabolic pathways which may be 
exploited for the discovery of new antimalarials.  These include targeting the synthesis 
of DNA precursors (69), fatty acid synthesis (71), glycolysis (72) , and de novo heme 
biosynthesis (73), among others.  Of relevance here, however, is inhibition of the 
formation of hemozoin.  One of the earliest effective treatments for malaria dating from 
the 17th century (74) was prepared from bark of Cinchona spp., The most active 
component of “Jesuit’s bark” was later identified as quinine, a potent inhibitor of BH 
formation (75).  Chloroquine, arguably the most successful antimalarial developed to 
this day, is an analogue of quinine and is thought to share a similar mechanism of 
action: inhibition of hemozoin formation.  Unfortunately, the efficacy of chloroquine has 
widely diminished in endemic areas due to rampant drug resistance. These resistant 
strains of P. falciparum exhibit several mutations in the Plasmodium falciparum 
chloroquine resistance transporter (PfCRT), a transmembrane vacuolar protein.  In 
resistant strains the accumulation of CQ within the digestive food vacuole is significantly 
less than in wild-type strains, as it is actively transported out of the DV (76).  
Nevertheless, hemozoin formation remains a valid drug target, as resistance is the result 
of diminished vacuolar accumulation of CQ, rather than changes to the hemozoin 
formation pathway itself.  Importantly, the interactions of hemozoin and antimalarial 
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inhibitors of this pathway have been studied in great detail, lending a wealth of 
information that can facilitate the drug discovery process. 
 
 Evaluating Small Molecule Interactions with Heme  
In order to understand the mode of action of hemozoin inhibitors, it is critical to 
understand possible interactions between these drugs and heme and or hemozoin.  
These efforts have been hampered by the insoluble nature of heme in a physiologically 
relevant environment. In vivo, the speciation of free heme preceding the formation of 
hemozoin is not fully understood, however, in vitro experiments reveal that free heme 
can exist as a monomer, or  several different dimeric species depending on 
environmental factors (Figure 11) (77). When investigating the interactions of heme 
with BH inhibitors, it is essential to identify the dominate species of heme present in 
solution as to facilitate a meaningful interpretation of the results. The primary dimeric 
forms of heme that are observed in solution are the π-π backbonding dimer (likely the 
most important species in hemozoin formation) (I), the µ-oxo dimer (II), and larger π 
bonding aggregates of µ-oxo dimers (III). The distribution of these heme species in vitro 
are reversible and can be regulated by careful control of the heme concentration, pH, 
salt content and solvent system in solution (78). At very low concentrations of heme in 
aqueous solutions or in the presence of a high percentage of organic solvent, heme can 
be solubilized and will exist mostly in the monomeric form (I) (79). This species of heme 
is important since monomeric heme would be the species of heme released during 
hemoglobin degradation. At higher concentrations of heme in aqueous solution, the π-π 
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dimer (II) will dominate (79). This is also true for protic solvent mixtures, since the 
conversion between µ-oxo dimer and the π-π dimer depend on the protonation of the 
oxygen bridging atom. This π-π species is likely the dominant form of heme present in 
the digestive food vacuole, so is perhaps the most important species of heme that 
should be studied in drug interactions.     
 
 
 
 
 
 
 
 
 
Figure 11.Speciation of heme in different environments. Heme can exist as a 
monomer (I), a π-π dimer (II), a µ-oxo dimer (III), or as π bonding aggregates of 
the µ-oxo dimer (IV). 
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Vacuolar Accumulation 
One of the confounding aspects of hemozoin inhibitors is that a compound’s 
ability to inhibit the formation of β-hematin in vitro will not necessarily have a direct 
correlation to the in vivo inhibition of hemozoin unless the drug can successfully 
accumulate within the digestive food vacuole (DV) of the parasite at the sight of 
nucleation and crystallization.  Consequently, targeting vacuolar accumulation is an 
important aspect of hemozoin inhibitor design.  The primary mode that results in the 
accumulation of a drug within the DV is by ‘pH trapping’ as is observed in the 
mechanism of action of CQ, amodiaquine and mefloquine, among others.  Here, 
lipophlic species that are neutral at physiological pH are capable of permeating cell 
membranes to gain entry into the malaria parasite.  Upon entry into the digestive food 
vacuole, however, the species has entered an acidic compartment (pH 4.8).  If 
protonatable functional groups are present (such as weakly basic functional groups), the 
species will become protonated and will no longer freely permeate the cell membrane, 
becoming trapped.  This pH trapping drives the accumulation of antimalarials within the 
digestive food vacuole.  In fact, using the known or calculated pKa values for BH 
inhibitors, the vacuolar accumulation ratio (VAR) can be easily determined using a 
modified Henderson-Hasselbach equation (Equation 1) (79, 80). 
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Equation 1. 
 
 
 
Using this idea of pH trapping, optimization of BH inhibitors using weakly basic 
functional groups could result in the accumulation of drug at the sight of action, which 
should reduce the IC50 of the drug.  This has been shown in the case of quinoline 
derivatives, where potency of the hemozoin inhibitor is increased as a function of 
increasing VAR. Therefore, compounds which are good inhibitors of BH formation but 
ineffective against P. falciparum could be potentially improved by the addition of weakly 
basic amine groups to improve vacuolar accumulation. 
 
Antimalarials and Small Molecule Inhibitors of BH formation  
Several antimalarial quinoline derivatives have been approved for human use 
including chloroquine, amodiaquine, mefloquine, primaquine and quinine (Figure 12), 
each of which is thought to act by inhibiting the formation of hemozoin.  The 
arylmethanol class of compounds includes halofantrine and lumefantrine and has also 
been used for the treatment of malaria (Figure 12).  Currently, none of these drugs are 
sufficient to combat the recurrence of malaria due to resistance, cost or adverse side-
effects, resulting in a need for the discovery of new antimalarial drugs. 
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Aside from the potent quinoline derivatives, many other small molecules are 
known to inhibit the formation of BH, including derivatives of benzimidazoles, 
xanthones, quinazolines, phenanthrenes, methylene blue and benzofurans, to name a 
few (Figure 13). The reason for the potency of these chemical scaffolds varies, but 
generally occurs via π-π interactions of the compound with the aromatic porphyrin ring 
and/or direct coordination to the Fe(III) center of heme.  Small molecule inhibitors of BH 
formation can interact not only with free heme, but also with the hemozoin crystal, or 
both, to inhibit formation of product.  It is important to understand the interactions of 
an active compound with heme to facilitate the design and optimization of new 
antimalarials targeting the hemozoin formation pathway. 
 
 
 
 
 
 
Figure 12. Structures of anti-malarial compounds of the quinoline and 
arylmethanol classes. 
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Quinoline Derivatives  
The interactions of many quinolines with heme have been documented.  In the 
case of free heme, spectroscopic evidence supports that CQ, AQ and mefloquine 
(among others) interact with the porphyrin ring via π-π stacking with the quinloline ring 
(79). In the 1960’s, it was first reported that CQ forms a complex with Fe(III)PPIX (81).  
Subsequent work in 1980 suggested that the targeting of heme by CQ may be the 
mechanism of action of the drug (82, 83).  Spectroscopically, the interactions of free 
heme with CQ are well described (84).  Upon titration of heme with CQ, there is a 
hypochromic shift in the soret band at 400 nm and a hyperchromic shift in the CT 
(charge-transfer) bands around 600 nm corresponding to the π-π interactions of CQ 
Figure 13. Structures of small molecule 
antimalarials. 
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with heme (85). Further support for the formation of a π-π complex is shown in the 
NMR spectrum of CQ following the addition of Fe(III)PPIX.  The paramagnetic Fe(III) has 
a strong effect on the spectrum of CQ, where paramagnetic shifts are observed for both 
1H and 13C (86, 87).  Paramagnetic shifts and relaxation data indicate the presence of a 
π-π complex rather than a coordination complex.  
It has also been proposed that some antimalarials such as the quinolines can 
absorb onto the surface of the hemozoin crystal itself, resulting in growth inhibition 
(88).  When subinhibitory concentrations of {3H}CQ were incubated with parasite 
cultures, electron autoradiographs of infected red blood cells revealed that the majority 
of the {3H}CQ was colocalized with the hemozoin crystal (88).  Later, a model of 
quinoline binding was proposed that suggested incorporation of CQ into the fast 
growing (89) corrugated faces of the crystal where grooves expose propionic acid 
groups, vinyl and methyl groups (90). CQ can intercalate the aromatic groups of the BH 
crystal and cap the (48) surface by forming a salt bridge between the quinoline amine 
and the propionic acid of the porphyrin, thereby inhibiting further growth of the crystal 
along this face. The CQ molecule would be further stabilized by interactions with the 
surrounding methyl and vinyl functional groups.   
The ability of many of these quinoline derivatives to accumulate within the 
digestive food vacuole explains the potency of these drugs against wild-type strains of P. 
falciparum. For CQ, a percentage of this weakly basic, lipophilic quinoline derivative is 
neutral at physiological pH. The protonatable tertiary amine and quinoline nitrogen 
atoms of CQ have respective pKa’s of 10.2 and 8.4. Consequently, as CQ passes into the 
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acidic (pH 4.8) DV, a portion of the drug becomes doubly protonated. The pH trapping 
effect can be quite large. In CQ treatment, nanomolar concentrations of the drug in 
plasma results in millimolar concentrations within the DV (89). This pH trapping effect 
can be observed for other quinoline antimalarials including mefloquine and 
amodiaquine. 
 
Arylmethanol Derivatives 
The arylmethanol family of compounds is another important class of quinoline 
derived antimalarials that have been shown to interact with Fe(III)PPIX (48).  This class 
of compounds includes quinine, mefloquine, lumefantrine and halofantrine, among 
others (Figure 13).  Recently, the halofantrine-Fe(III)PPIX crystal structure was solved, 
revealing that interactions occur with monomeric heme, but not dimeric heme (90).  
The hydroxyl group of halofantrine coordinates directly to the Fe(III) center of heme 
resulting in a five coordinate porphyrin complex.  The hydroxide functionality of 
halofantrine has a pKa of ~14 and would be expected to exist exclusively in the 
protonated state in the acidic DV.  However, the Fe(III)-O bond length (1.840(4) Å) 
suggests the formation of an alkoxide bond (1.816 – 1.851 Å) and not an Fe(III)-alcohol 
bond (2.113 – 2.160 Å).  The depression of the hydroxyl pKa may be due to the strong 
coordination to the Fe(III) atom which induces a pKa shift.  Additionally, π-stacking of the 
phenanthrene and porphyrin was confirmed.  The unprotonated propionate of 
Fe(III)PPIX interacts with both the protonated N atom of halofantrine and the propionic 
acid group of a neighboring heme.      
36 
 
 
 Xanthones 
 Several other classes of BH inhibitors have been identified for potential use as 
antimalarial drugs including the xanthones.  Xanthones are known to exist naturally as 
secondary metabolites primarily of the Guttiferae and Gentianaceae family of plants, 
and were first identified for antimalarial activity by Riscoe and Winter (85, 91).  Soon 
after the discovery of the antiplasmodial activity of the xanthones, Ignatushchenko et al. 
observed that these compounds exhibited stage specifity, noting that trophozoites were 
more sensitive than were ring-stage parasites (92).  This observation followed studies 
that hypothesized heme as the potential drug target of these compounds (93, 94). It was 
also shown that the xanthone derivative 2,3,4,5,6-pentahydroxyxanthone (Figure 14a) 
formed a soluble complex with free heme. Later, the interactions between 45X2 (Figure 
14b) and heme were examined in detail using NMR spectroscopy (93).  These studies 
demonstrated that the xanthone carbonyl moiety coordinates to the Fe(III) center of 
heme. Further, hydrogen bonding between the hydroxyl groups of 45X2 and the 
propionate side chains of heme were observed in addition to π-π stacking of the 
aromatic regions of both species. The ratio of xanthone:heme was found to be 1:2 for 
45X2.  Since the discovery of xanthone activity against the parasite, studies have sought 
to increase the potency of these compounds.  The 3,6-bis-ω-
diethylaminoalkoxyxanthone class of xanthone derivatives developed by Kelly et al. 
boasted an increased affinity for heme binding that resulted in an increased potency 
against the parasite (95).   
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Artemisinin  
 This sespuiterpene trioxane lactone contains a peroxide bridge, which is crucial 
to its activity (96).  In the presence of this drug, heme acts both as an activator and a 
target of artemisinin free radicals.  As an activator, heme catalyzes the opening of the 
peroxide bridge of artemisinin, thereby promoting the formation of carbon-centered 
free radicals (97).  The resultant radicals cannot be cyclically oxidized and reduced (98), 
therefore only one free radical can result from a single drug molecule. Instead of being 
cyclically regenerated, the radicals form covalent bonds with targets.  Heme is also an 
important target of alkylation by artemisinin free radicals, where the free radicals have 
been found to form covalent bonds with heme.  Artemisinin free radicals also form 
covalent adducts with certain parasite proteins including the heme-binding 
Figure 14. Structures of Xanthone and antimalarial xanthone derivatives 
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translationally controlled tumor protein (TCTP), and in membrane containing structures 
including the plasma membrane, endoplasmic reticulum, nuclear envelope, digestive 
vacuole membrane, and mitochondria (99-102). Because artemisinin and its derivatives 
are activated by free heme, it represents a very parasite specific malaria treatment. 
   
High-Throughput Screening and Drug Discovery 
 With parasite antimalarial resistance on the rise, there is a pressing need for the 
discovery of novel chemical scaffolds that are active against Plasmodium spp.  One 
discovery technique is high-throughput screening (HTS), where thousands to millions of 
small molecules are rapidly tested for activity in assay.  An HTS suitable assay is 
generally formatted for use in 384- or 1536-well microtiter plates in order to test a large 
quantity of compounds in a small amount of time.  Furthermore, an HTS amenable assay 
must involve minimal processing steps, be highly robust and should be comprised of 
easily accessible reagents at a minimal cost.  Assays can be either phenotypic or target-
based in nature.  In antimalarial HTS, phenotypic assays are those that seek to identify 
small molecules that are capable of killing the parasite itself in P.falciparum infected 
erythrocytes.  The disadvantage to this approach is that the mechanism of action of 
inhibitors is unknown, and can be quite difficult to elucidate.  In target-based assays, a 
specific cellular process, such as hemozoin formation, is used to identify potential 
antimalarials.  Inhibitor/target interactions can be studied immediately after identifying 
hits, an advantage over phenotypic screening.  An additional advantage is the option to 
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select pathways that are specific to the parasite.  The disadvantage to target-based 
screening is that activity does not necessarily confer to the whole-cell assay.     
The use of HTS in antimalarial drug discovery has been utilized in recent years for 
both target-based and phenotypic assays (103). Of the target based assays, several have 
been developed for the purpose of identifying inhibitors of BH formation (104-108).  
One of the first successful assays developed for use in HTS utilized radioactive 14C-
labeled hematin to quantitate BH formation using scintillation counting (109-114).  
Crystallization was mediated by the addition of lipid-rich extracts from parasite lysates.  
The semi-automated assay tested over 100,000 compounds in 96-well plates and 
identified 45 nonquinoline hits.  Of these 45 compounds, the structural classes of 
compounds identified included triarylcarbinols, piperazines, benzophenones, imides, 
hydrazides, indoles and isoxazoles.  The non-quinoline hits were then tested in a 
secondary whole-cell assay consisting of cultures of CQ-sensitive and CQ-resistant P. 
falciparum. Four compounds were identified to have activity in both strains at 
concentrations of <5 µM (the IC50 of CQ in sensitive strains of P. falciparum is ~25 nM).  
Though few of the compounds identified in the BH inhibition screen were active against 
parasite cultures, the ability of HTS to identify novel pharmacophores supported the 
utility of this approach.  However, this assay was not utilized to its full potential due to 
deficiencies in design.  The semi-automated use of 96-well plates would be considered a 
medium-throughput method compared to the more often used 384- and 1536- well 
plates.  Further, the need for trophozoite lysates and radioactive hematin limits the use 
of this assay to laboratories capable of maintaining parasite cultures and open to the 
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restrictions imposed by utilizing radioactive substrates.  Fortunately, subsequent BH 
formation assays have improved upon the original protocol by increasing the 
throughput of compound screening, incorporating more readily available substrates, 
and using improved methods of quantification that do not require the use of radio-
labeled heme. 
In 2009, Clardy and coworkers developed a true HTS assay that utilizes acetate 
buffer for the synthesis of BH in 384-well microtiter plates (113, 115, 116).  In this assay, 
a high concentration (9.7 M, pH 4.8) of sodium acetate buffer is utilized to mediate the 
formation of BH by solubilizing Fe(III)PPIX, the rate limiting step in BH formation.  The 
assay is incubated at 60⁰C for 120 min, then analyzed using the pyridine ferrichrome 
method of quantification developed by Egan and coworkers (114).  Using this assay to 
screen 16,000 compounds at a 220 µM concentration of test compound, 644 hits (3.96% 
hit-rate) capable of inhibiting >50% BH formation were identified.  Of these 644 hits, 17 
were identified as active against in vitro cultures of P. falciparum (hits were identified as 
having activity of >80% against the parasite).  As a direct result of this screening effort, 
the authors identified two novel classes of compounds that show activity in both the BH 
formation assay, as well as the whole-cell parasite assay.  Two classes of compounds, 
the pyrimidine and 1,3-benzoxathiol-2-one compounds were identified in this screen.  
While this assay was a major improvement upon previously published medium-
throughput assays, the conditions for BH formation were not physiologically relevant.  
This is perhaps the reason that so few of the BH inhibitors show activity against cultures 
of P. falciparum.       
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 Improved understanding of the in vivo formation of hemozoin has facilitated 
advances in HTS assay design for the discovery of novel BH inhibitors.  Of vital 
importance is the identification of neutral lipids as playing a role in hemozoin formation 
(117). The composition of these lipids has been found to mediate the formation of BH 
and is inhibited upon co-incubation with the quinoline antimalarials.  Due to the 
relatively high cost of these neutral lipids, they are not practical for use in HTS.  An 
alternative is the use of commercially available, low cost detergents, several of which 
have been shown to mediate formation of BH in 96- and 384-well plate format in vitro 
and in HTS formats (116) (65).  The assay uses the lipophilic detergent, NP-40, to 
mediate BH crystallization at a pH of 4.9 (116, 118).  Further, when co-incubated with 
CQ or AQ, NP-40 exhibits similar IC50’s to those obtained when using the neutral lipid 
blend.  Using this assay, a pilot screen of over 38,000 compounds resulted in the 
identification of 161 hits, a 0.42% hit-rate.  IC50 values were obtained for each of these 
hits and included the identification of 113 compounds with lower IC50 values than that 
of AQ in this assay.  These compounds were then tested for efficacy against P.falciparum 
infected erythrocytes and 48 compounds were identified as capable of inhibiting >90% 
of parasitemia, including the identification of eight compounds with activities at 
nanomolar concentrations (Figure 15a).  Four distinct chemical scaffolds were identified 
(Figure 15b). 
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Conclusion 
 In order to survive, the malaria parasite relies on a unique detoxification 
pathway in which toxic free heme is converted to the nontoxic biomineral hemozoin.  
Disruption of this crystallization process results in parasite death, and therefore serves 
as an important strategy for drug design.  Hemozoin formation does not occur 
Figure 15. (a) Structures of antimalarial compounds found to be 
active in the malaria parasite, and (b) four distinct chemical 
scaffolds. 
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spontaneously at a physiologically relevant rate, and identification of the biological 
mediator of this crystal remained elusive for many years.  Recently, neutral lipid bodies 
present within the digestive food vacuole of the parasite have been replicated in vitro 
(SNLDs).  It has been found that Fe(III)PPIX rapidly accumulates within these SNLDs.  
Furthermore, the SNLDs have been shown to serve as a kinetically competent site for BH 
formation.  These data demonstrate that the neutral lipid bodies are the biological 
mediator of hemozoin formation.  Using this information, an assay that mimics the 
physiological environment in which hemozoin formation takes place has been 
developed and used in high-throughput screening to identify novel inhibitors of this 
target.  Furthermore, the interactions of hemozoin inhibitors with free heme have been 
studied in detail.  These studies have revealed that inhibitors can interact through π-π 
interactions and/or direct coordination to the Fe(III) center, inhibiting the incorporation 
of the heme into the growing hemozoin crystal.  The information gained from these 
interactions can now be used to optimize compounds that inhibit BH formation.  All of 
these advances have only been made possible by first understanding the formation of 
the biomineral, hemozoin.     
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Chapter II 
 Isolation of Anti-malarial Compounds from a Natural Product Library 
 
Introduction 
Natural products have long been the single most productive source of leads for 
drug development (119). Between 1981 and 2002, 49% of all small-molecule New 
Chemical Entities (NCEs) were natural products, natural product analogues, or natural 
product derivatives (120). In fact, the anti-malarial drug chloroquine is derived from 
quinine, a natural product found in the bark of the Cinchona tree (See figure 12). 
Despite the success of natural products in the drug discovery field, the emphasis on 
natural product drug discovery has waned in the past decade for several reasons.  
First, the emergence of combinatorial libraries and their promise of many 
potential biologically active compounds, short timelines, and high-throughput 
capabilities took the focus away from the slow process of natural product purification, 
screening, structure elucidation, and subsequent scale-up (119). Secondly, the increase 
in molecular biology, genomics, and cellular biology techniques made the discovery of 
new drug targets possible, increasing the demand for shorter drug discovery timelines. 
Finally, the reduction of emphasis on infectious disease research - a typical strong point 
of many biologically active natural products - encouraged scientists to move from 
natural product screening to screening much larger, synthetic libraries (120). 
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Utilizing the new technologies born from the combinatorial chemistry drug 
discovery era, science is once again turning to natural product drug discovery to 
produce useful biologically active compounds. Many bioactive compounds discovered 
previously have come from a class of soil bacteria called actinomycetes. This class of 
bacteria has been the main producer of approved antibiotics and other biologically 
active metabolites to date such as the well-known antibiotics streptomycin and 
erythromycin (see Figure 16 )(121). 
 
 
 
 
 
 
 
 
 
In this project we investigate this class of bacteria again, and screen a library of 
cave actinomycetes provided by the Bachmann lab for β-hematin inhibition activity 
using the β-hematin formation assay optimized by the Wright Lab (122). This 
Figure 16. Structures of Streptomycin and Erythromycin, antibiotics 
isolated from Actinomycete bacteria. 
Streptomycin Erythromycin 
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actinomycete library has already gone through a pre-screen in the Wright lab, producing 
41 active actinomycete extracts to replicate and test in this study. Figure 17 provides an 
overview of the discovery and hit identification process. This process is described in 
detail in the Experimental section of this chapter. 
 
 
 
 
Actinomycetes 
Actinomycetes are a species of soil bacteria that have been shown to be 
successful producers of bioactive compounds. They are responsible for the production 
Figure 17. Overview of hit discovery and identification from 
Actinomycete strains. 
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of nearly half of all discovered bioactive secondary metabolites (123). This species has 
been the source of antibiotics, antitumor agents, and immunosuppressive agents and 
the subject of intensive study (123-125). Recently, success of isolation of novel 
compounds from terrestrial actinomycetes has declined, and the re-isolation of 
previously discovered compounds has increased (126). Therefore, a need for novel 
bioactive compounds from actinomycetes is presented. Screening of new actinomycete 
strains from unexplored or unexploited environments, such as caves, promises to 
uncover an array of novel bioactive compounds. 
Experimental 
Growth of Actinomycete Culture 
30 µL of an Actinomycete strain were grown on individual solid agar plates for one week 
at 30°C. Individual colonies were then seeded into six separate flasks containing 50 mL 
of liquid media, and allowed to incubate at 30°C with shaking for one week. 25mL of 5 of 
the seed cultures was inoculated into separate 500mL production cultures, and allowed 
to incubate at 30°C with shaking for one week. This produced 5L of total bacteria 
culture.  
Purification of actinomycete extracts 
The 5L of bacterial culture was extracted with an equal amount of solvent, incubated 
with shaking for 30 minutes, and the resulting mixture spun down at 3500 rpm for 5 
minutes. The solvent was removed from the aqueous media, and dried by Rotovap, 
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producing a crude extract. The crude extract was then purified using both a Sephadex 
LH-20 column (100% MeOH) and LC-ESI-MS (A: 95% Acetonitrile: 5% H2O, 1mM 
ammonium Accetate, B: 95% H2O: 5% Acetonitrile, 1mM Ammonium Acetate) to 
produce two sets of extract fractions. These resulting fractions were transferred to 96-
well plates, dried, and screened using the β-hematin formation assay (122).  
Detergent mediated β-hematin formation assay  
The assay conditions were as follows: All liquid delivery was automated using a Thermo 
Scientific Multidrop Combi robot. To suspend each natural product well fraction, 5-10 μL 
of acetonitrile was added followed by ten minutes of shaking and 65 μL of water. A 20 
μL volume of the hemozoin formation promoter NP-40 (30.55 μM) and 5 μL acetone 
were added. Finally, a 90 μL volume of hematin (222.2 μM) suspended in 2.0 M sodium 
acetate solution (pH 4.8) was added to give a final volume of 100 μM hematin. Each 
plate was incubated at 3  C and 55 rpm for at least 5 hours. Upon completion, the assay 
wells were treated with 25 μL of 50% pyridine solution (pH  .5) and the plates were 
shaken for 10 minutes. The absorbance was read at 405 nm using a SpetraMax M5 
microplate reader and data was plotted using GraphPad Prism 4. A plate of water and 
amodiaquine at the IC50 was run as negative and positive controls for inhibition. 
Fractions which showed activity were combined, and put through another round of 
purification and screening. Rounds of purification and screening were performed until 
pure fractions containing only active compounds were obtained. The pure compounds 
were then analyzed by 2D NMR. 
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2D NMR structure elucidation of Pure Compounds 
Active compounds were dissolved in CH3OD (Sigma Aldrich), and added to a 3mm or 
5mm NMR tube. Samples were run using a Bruker AV-II 600 MHz NMR spectrometer. 
Samples were used for 1D 1H-NMR experiments, as well as 2D NMR suite experiments 
(COSY, HMBC, HSQC). Data obtained from these experiments will be analyzed, and 
structures elucidated.  
MSF Assay 
10mM samples of each active compound will then be tested in an MSF assay following a 
modified version of the protocol outlined by (113). Briefly, active compounds dissolved 
in DMSO will be prescreened at 23 μM at a 0.3% starting parasitemia (at 2% hematocrit) 
in 384-well optical-bottom plates. To establish dose-response curves, active compounds 
will be delivered in a range of concentrations from 0 to 23 µM with a final DMSO 
concentration of 0.23% per well. To ensure that DMSO does not interfere with parasite 
growth, a control plate will be used containing wells with 0.23% DMSO, and wells 
containing no DMSO will also be used. Concentration-response curves will be generated 
using GraphPad Prism v5.0 
Results 
Of the 41 active actinomycete extracts discovered in the preliminary screening, So far, 
we have been able to reproduce screening data for 5 Actinomycete strains in the 
Bachmann library (See figure 6). See Appendix A for graphs of all fractions for these 
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strains. Of the 5 strains for which we were able to reproduce screening data, we found 
two compounds that were active both in vitro and in vivo. The first compound 
(Compound A) was found in an actinomycete strain identified as BBHARD25. Compound 
A was found to elute at 19.19 minutes using HPLC (A: 95% Acetonitrile: 5% H2O, 1mM 
Ammonium Acetate; B: 95% H2O: 5% Acetonitrile, 1mM Ammonium Acetate). Using the 
NELI program, we were able to compare HPLC trace with mass and activity data (see 
figure 18). 
 
 
 
 
The NELI data shows an active (highlighted) peak at 19.19 minutes. The LC-MS Mass 
data of the peak shows a relatively pure Compound A with an m/z of 270.55. Accurate 
mass data of Compound A showed an m/z of 271.06 the difference in m/z 
measurements for Compound A are too small to be fragments, and so are most likely 
due to differences in MS instrumentation. 13C NMR analysis of Compound A showed the 
presence of 1 carbonyl carbon, 12 aromatic carbons, 1 tertiary, and 1 secondary carbon. 
m/z  
270.55  
   
Figure 18.  NELI data of BBHARD25 overlapping HPLC data with activity. LC-MS data is 
shown on the right. 
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A search of the accurate mass and structural components in the Dictionary of Natural 
Products database suggested Genistein as a possible identity, while comparison of 2D 
NMR data of Compound A with known 2D NMR values of Genistein confirmed the 
identity of Compound A as the soy isoflavone Genistein (Table 1, Figure 19). 
 
carbon δC δH  HMBC correlations 
1 180 C 8, 6 
2 104.6 C 4, 6 
3 162.9 C 4 
4 98.8 CH 6.23 (d) 
 5 164.9 C 4, 6 
6 93.3 CH 6.35 (d) 
 7 158.9 C 8, 6 
8 152.9 CH 8.07 (s) 
 9 121.8 C 12, 14 
10 123.3 C 8, 11, 15 
11 130 CH 7.39 (d) 12, 14 
12 114.8 CH 6.87 (d) 11, 15 
13 157.4 C 11, 12, 14, 15 
14 114.8 CH 6.87 (d) 11, 15 
15 130 CH 7.39 (d) 12, 14 
 
 
 
 
 
 
Table 1. 13C, 1H, and HMBC data for Compound A (600 MHz in CD3O3) 
Figure 19. Structure of Genistein with 
13
C and 
1
H NMR shifts labeled. 
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The second compound (Compound B) that was found to be active in vitro and in vivo 
was isolated from an actinomycete strain identified as BBHARD23. Compound B was 
found to elute from HPLC at 22.20 minutes HPLC (A: 95% Acetonitrile: 5% H2O, 1mM 
Ammonium Acetate; B: 95% H2O: 5% Acetonitrile, 1mM Ammonium Acetate). NELI data 
of Compound B shows an active peak at 22.20 minutes. The LC-MS mass data of the 
peak shows a major compound with an m/z of 375.75 (See Figure 20), and accurate 
mass data of Compound B showed an m/z of 376.13. The small difference in m/z 
measurements can be explained by differences in MS instrumentation.  Preliminary 13C 
NMR data of Compound B suggests the presence of 2 carbonyl carbons, 5 methylene 
carbons, 8 methnine carbons, and 10 quaternary carbons. A full 2D NMR analysis of 
Carbon B is in progress. 
 
 
 
 
 
 
 
 
m/z  
375.71   
   
Figure 20.  NELI data of BBHARD23 overlapping HPLC data with activity. LC-MS data is 
shown on the right. 
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Conclusion 
We were able to reproduce results from the initial screening, and found that the 
Bachmann lab Actinomycete library produced many active fractions. Two fractions that 
were active in the β-hematin assay were purified to produce two active compounds. 
One of these compounds (Compound A) was identified by MS data and 2D NMR as the 
soy isoflavone Genistein. It is most likely that Genistein was obtained as a media 
component, instead of a product of Actinomycete metabolism, since Actinomycete 
growth media used in this study routinely contained ground soybeans. Structure 
determination of Compound B by MS and 2D NMR is in progress. 
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Chapter III 
 Anti-malarial Effects of Genistein 
 
Introduction 
Genistein is an isoflavonoid commonly found in soybeans. It is the simplest of the 
isoflavanoid compounds, and an important precursor to more complex isoflavanoids 
that have antimicrobial action (127). Studies on Genistein show it to have tyrosine 
kinase activity, and action against cancer and cardiovascular disease (127). Genistein has 
also been found to be active against liver and blood stage malaria parasite, reducing 
liver infections by 64% in mice given Genistein 6hrs prior to infection, and blood 
infections by 33% when administered at 200uM (128, 129).The antimalarial activity of 
genistein in these studies was attributed to its function as a tyrosine kinase inhibitor, 
but no link to any interaction with hemozoin has been found. In this study, we found the 
active component of an actinomycete extract to be genistein. 
 
Experimental 
Growth of Actinomycete Culture 
30 µL of an Actinomycete strain were grown on individual solid agar plates for one week 
at 30°C. Individual colonies were then seeded into six separate flasks containing 50 mL 
55 
 
of liquid media, and allowed to incubate at 30°C with shaking for one week. 25mL of 5 of 
the seed cultures was inoculated into separate 500mL production cultures, and allowed 
to incubate at 30°C with shaking for one week. This produced 5L of total bacteria 
culture.  
Purification of actinomycete extracts 
The 5L of bacterial culture was extracted with an equal amount of ethylacetate,, 
incubated with shaking for 30 minutes, and the resulting mixture spun down at 3500 
rpm for 5 minutes. The solvent was removed from the aqueous media, and dried by 
Rotovap, producing a crude extract. The crude extract was then purified using both a 
Sephadex LH-20 column (100% MeOH) and LC-ESI-MS (A: 95% Acetonitrile:5% H2O, B: 
5% Acetonitrile: 95% H2O, 1mM Ammonium Acetate) to produce two sets of extract 
fractions. These resulting fractions were transferred to 96-well plates, dried, and 
screened using the β-hematin formation assay (46).  
Detergent mediated Β-hematin formation assay  
The assay conditions were as follows: All liquid delivery was automated using a Thermo 
Scientific Multidrop Combi robot. To suspend each natural product well fraction, 5-10 μL 
of acetonitrile was added followed by ten minutes of shaking and 65 μL of water. A 20 
μL volume of the hemozoin formation promoter NP-40 (30.55 μM) and 5 μL acetone 
were added. Finally, a 90 μL volume of hematin (222.2 μM) suspended in 2.0 M sodium 
acetate solution (pH 4.8) was added to give a final volume of 100 μM hematin. Each 
plate was incubated at 3  C and 55 rpm for at least 5 hours. Upon completion, the assay 
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wells were treated with 25 μL of 50% pyridine solution (pH  .5) and the plates were 
shaken for 10 minutes. The absorbance was read at 405 nm using a SpetraMax M5 
microplate reader and data was plotted using GraphPad Prism 4. A plate of water and 
amodiaquine at the IC50 was run as negative and positive controls for inhibition. 
Fractions which showed activity were combined, and put through another round of 
purification and screening. Rounds of purification and screening were performed until 
pure fractions containing only active compounds were obtained. The pure compounds 
were then analyzed by 2D NMR. 
2D NMR structure elucidation of Pure Compounds 
Active compounds were dissolved in CH3OD (Sigma Aldrich), and added to a 3mm or 
5mm NMR tube. Samples were run using a Bruker AV-II 600 MHz NMR spectrometer. 
Samples were used for 1H-NMR experiments, as well as 2D NMR suite experiments 
(COSY, HMBC, HSQC). Data obtained from these experiments will be analyzed, and 
structures elucidated.  
MSF Assay 
10mM samples of each active compound will then be tested in an MSF assay following a 
modified version of the protocol outlined by (113). Briefly, active compounds dissolved 
in DMSO will be prescreened at 23 μM at a 0.3% starting parasitemia (at 2% hematocrit) 
in 384-well optical-bottom plates. To establish dose-response curves, active compounds 
will be delivered in a range of concentrations from 0 to 23 μM with a final DMSO 
concentration of 0.23% per well. To ensure that DMSO does not interfere with parasite 
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growth, a control plate will be used containing wells with 0.23% DMSO, and wells 
containing no DMSO will also be used. Concentration-response curves will be generated 
using GraphPad Prism v5.0 
Results 
MSF assays of the Genistein isolated from BBHARD25 and the isolated active fraction 
from BBHARD23 showed very little activity. The IC50 values of these fractions were 
18µM, an order of magnitude less active than chloroquine (See figure 21).  To confirm 
that Genistein is the active compound, a β-hematin assay was performed on synthetic 
Genistein. The IC50 curves of the β-hematin assay performed on synthetic Genistein 
showed no activity (See figure 22). Therefore, it is likely that Genistein was not the 
major contributor of activity in the β-hematin assay from BBHARD25. Further analysis of 
NELI data shows the presence of another compound at very low levels (See Figure 23). 
LC-MS data shows that the second compound has an m/z of 412.72. Efforts to obtain 
NMR and accurate mass data from this compound were unsuccessful due to the limited 
amount of sample that was left, and the low concentration of the compound. 
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Figure 22: IC50 curve of synthetic genistein performed under normal assay conditions. 
Figure 21: MSF assay IC50 curves of active fractions from BBHARD23 and BBHARD25  
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Figure 23. NELI data of BBHARD25 overlapping HPLC data with activity. LC-MS data is shown on 
the right, revealing the presence of a second compound with m/z of 412.72. 
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Conclusion 
Although the isolated genistein did not show high levels of activity in vivo, it is promising 
that activity can be seen in the malaria parasite even at low levels. Using SAR studies, it 
may be possible to modify the active scaffolds to increase antimalarial activity, thereby 
producing a novel antimalarial treatment. Since synthetic Genistein showed no activity 
in vitro, this suggests that another compound was responsible for that activity. The 
second compound found in the active fraction at low levels it is also possible that 
another compound present at very low levels is causing the anti-malarial activity in the 
β-hematin assay. This is interesting because any compound producing anti-malarial 
activity at such low levels is probably very potent. Efforts to obtain NMR and accurate 
mass data from this unknown compound were unsuccessful due to the limited amount 
and low concentration of the sample. A more concentrated sample may be obtained by 
growing another culture of the BBHARD25 actinomycete strain, and re-isolating the 
unknown compound. 
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Appendix A 
β-HEMATIN ASSAYS OF ACTINOMYCETE STRAINS 
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APPENDIX B 
CHROMOTOGRAPHY PROFILES OF ACTIVE COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NELI data of BBHARD25 HPLC trace overlapped with activity data. 
 NELI data of BBHARD23 HPLC trace overlapped with activity data. 
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APPENDIX C 
MASS ANALYSIS DATA OF BBHARD 25 AND BBHARD23 
 
 
 
 
 
 
 
 
Mass analysis data of active component of BBHARD25 
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APPENDIX C CONT. 
MASS SPECTROMETRY DATA OF BBHARD25 AND BBHARD23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass analysis data of active fraction from BBHARD23 
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APPENDIX D 
NMR DATA OF BBHARD25 
 
 
 
 
 
 
 
 
 
 
 
 
 
COSY NMR data of active component of BBHARD25 
1
H NMR data of active component of BBHARD25 
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APPENDIX D CONT. 
NMR DATA OF BBHARD25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSQC NMR data of active component of BBHARD25 
HMBC NMR data of active component of BBHARD25 
74 
 
APPENDIX E 
CURRICULUM VITAE 
 
HOLLY MARIE CARRELL 
 
EDUCATION 
Vanderbilt University, Nashville, TN 
M.S. in Chemistry                                                                                                         2013 
Thesis: “Isolation and Characterization of Anti-malarial Compounds From a Natural 
Product Library” 
 
Oakwood University, Huntsville, AL  
B.S. in Biochemistry                                                                                                      2009 
 
 
AWARDS 
Provost’s Graduate Fellowship, Vanderbilt University                                     2009 – Present 
Premier Scholarship, Oakwood University                                                           2005 – 2009 
 
TEACHING EXPERIENCE 
Vanderbilt University, Nashville, TN 
Teaching Assistant – to Professor Adam List in “Organic Chemistry Lab” 2010-2012 
Supervised lab experiments, held office hours, administered quizzes and lab final, 
documented all grades. 
Oakwood University, Huntsville, AL 
Teaching Assistant – to Professor Kenneth LaiHing in “Organic Chemistry Lab” 2008 
Supervised lab experiments, administered quizzes and lab final, documented all grades. 
Teaching Assistant – to Professor Kenneth LaiHing in "General Chemistry Lab” 2006-
2007 
Supervised lab experiments, administered quizzes and lab final, documented all grades. 
RELATED EXPERIENCE 
Vanderbilt University, Nashville, TN 
Graduate Research assistant – to Professor David Wright                               2009 – 2012 
75 
 
Experiment design and execution, data collection and analysis on isolating and 
identifying antimalarial probes from a natural product library. 
Oakwood University, Huntsville, AL 
Research Assistant – to Professor Alexander Volkov                                          2007 – 2009 
Design and execute experiments on the electrophysiology of the Venus Flytrap, data 
collection and analysis. 
Oakwood University, Huntsville, AL 
Research Assistant – to Professor Christopher Perry 2006-2008 
Responsible for data collection by Atomic Force Microscopy on various projects. 
Donald Danforth Plant Science Center, St. Louis, MO 
Research Intern 2007 
Conducted research on the mode of action of plant defensins in the inhibition of 
Fusarium graminearum. 
PUBLICATIONS AND PAPERS 
Sandlin, Rebecca D., Holly M. Carrell, and David W. Wright. "Hemozoin: Crystal 
Engineering Survivability." Encyclopedia of Inorganic and Bioinorganic Chemistry. 
Volkov, Alexander G., Holly Carrell, and Vladislav S. Markin. "Biologically closed electrical 
circuits in Venus flytrap." Plant Physiology 149.4 (2009): 1661-1667. 
Volkov, Alexander G., et al. "Electrical memory in Venus 
flytrap."Bioelectrochemistry 75.2 (2009): 142-147. 
Volkov, Alexander G., Holly Carrell, and Vladislav S. Markin. "Molecular electronics of 
the Dionaea muscipula trap." Plant signaling & behavior 4.4 (2009): 353-354. 
Volkov, Alexander G., et al. "Plant electrical memory." Plant signaling & behavior 3.7 
(2008): 490-492.  
Waddell, Emanuel A., et al. "Surface modification of Sylgard 184 polydimethylsiloxane 
by 254nm excimer radiation and characterization by contact angle goniometry, infrared 
spectroscopy, atomic force and scanning electron microscopy." Applied Surface 
Science 254.17 (2008): 5314-5318. 
 
 
 
 
 
76 
 
REFERENCES 
 
1. Perutz, M. F., Sci. Am. 1978, 239 (6), 92. 
 
2. Wittenberg, B.; Wittenberg, J., Annu. Rev. Physiol. 1989, 51 (1), 857. 
 
3. Mason, H., Science. 1957, 125 (3259), 1185. 
 
4. Gong, W.; Hao, B.; Mansy, S. S.; Gonzalez, G.; Gilles-Gonzalez, M. A., Chan, M. K., Proc. 
Natl. Acad. Sci. 1988, 95 (26), 15177. 
 
5. Nath, K. A.; Balla, J.; Croatt, A. J.; Vercellotti, G. M., Kidney 
Int. 1995, 47 (2), 592. 
 
6. Nath, K.A., Vercellotti, G.M., Grande, J.P., Miyoshi, H., Paya, C.V., Manivel, J.C., 
Haggard, J.J., Croatt, A.J., Payne W.D., Alam, J., Kidney Int. 2001, 59 (1), 106. 
 
7. Aft, R., Mueller, G., J. Biol. Chem. 1984, 259 (1), 301. 
 
8. Miller, Y. I., Shaklai, N., Biochem. Mol. Biol. Int. 1994, 34 (6), 1121. Epub 1994/12/01. 
 
9. Suliman, H. B., Carraway, M. S., Velsor, L. W., Day, B. J., Ghio, A. J., Piantadosi, C. A., 
Free Radical Biol. Med. 2002, 32 (3), 246. 
 
10. Castellani, R., Harris, P., Lecroisey, A., Izadi-Pruneyre, N., Wandersman, C., Perry, G., 
Smith, M. A., Antioxid. Redox Signaling. 2000, 2 (1), 137. 
 
11. Kutty, R., Daniel, R. F., Ryan, D. E., Levin W., Maines, M. D., Arch. Biochem. Biophys. 
1988, 260 (2), 638. 
 
12. Docherty, J.C., Firneisz, G.D., Schacter, B.A., Arch. Biochem. Biophys. 1984, 235 (2), 
657. 
 
13. Ryter, S.W., Tyrrell, R.M., Free Radical Biol. Med. 2000, 28 (2), 289. 
 
14. Tenhunen, R., Marver, H.S., Schmid, R., J. Biol. Chem. 1969, 244, 6388. 
 
15. Francis, S.E., Sullivan, D.J., Goldberg, D.E., Annu. Rev. Microbiol. 1997, 51 (1), 97. 
 
16. Morrison, D.B., Jeskey, H.A., J. Natl. Malar. Soc. 1948, 7 (4), 259. Epub 1948/12/01. 
 
77 
 
17. Ball, E., McKee, R., Anfinsen, C., Cruz, W., Geiman, Q., J. Biol. Chem. 1948, 175 (2), 
547. 
 
18. Orjih, A.U., Fitch, C.D., Biochim. Biophys. Acta. 1993, 1157 (2), 270. 
 
19. Sherman, I., Bull. World Health Organiz.1977, 55 (2–3), 265. 
 
20. Ting, I.P., Sherman, I.W., Comp. Biochem. Physiol. 1966, 19 (4), 855. 
 
21. Alan, F. C., Brendan, S. C., Cell. 2006, 124, 755. 
 
22. Sherman I.W., Tanigoshi, L., Int. J. Biochem. 1970, 1 (5), 635. 
 
23. Theakston, R.D., Fletcher, K.A., Maegraith, B.G., Ann. Trop. Med. Parasitol. 1970, 64 
(1), 63. Epub 1970/03/01. 
 
24. McCormick, G.J., Exp. Parasitol. 1970, 27 (1), 143. 
 
25. Slomianny, C., Blood Cells. 1990, 16 (2–3), 369. Epub 1990/01/01. 
 
26. Olliaro, P., Goldberg, D., Parasitol. Today. 1995, 11 (8), 294. 
 
27. Goldberg, D., Slater, A., Cerami, A., Henderson, G., Proc. Natl. Acad. Sci. U. S. A., 
1990, 87 (8), 2931. 
 
28. Francis, S.E., Gluzman, I.Y., Oksman, A., Banerjee, D., Goldberg, D.E., Mol. Biochem. 
Parasitol. 1996, 83 (2), 189. 
 
29. Gluzman, I.Y., Francis, S.E., Oksman, A., Smith, C.E., Duffin, K.L., Goldberg, D.E., J. 
Clin. Invest. 1994, 93 (4), 1602. 
 
30. Kolakovich, K.A., Gluzman, I.Y., Duffin K. L., Goldberg, D. E., Mol. Biochem. Parasitol. 
1997, 87 (2), 123. 
 
31. Coombs, G., Goldberg, D., Klemba, M., Berry, C., Kay, J., Mottram, J., Trends 
Parasitol. 2001, 17 (11), 532. 
 
32. Berry, C., Humphreys, M., Matharu, P., Granger, R., Horrocks. P., Moon, R., Certa, U., 
Ridley, R.G., Bur, D., Kay, J.,  FEBS Lett. 1999, 447 (2–3), 149. 
 
33. Goldberg, D., Slater, A., Beavis, R., Chait, B., Cerami, A., Henderson, G., J. Exp. Med. 
1991, 173 (4), 961. 
 
78 
 
34. Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M., Goldberg, D. E., Proc. Natl. 
Acad. Sci. 2002, 99 (2), 990. 
 
 
35. M. F. Perutz, M.F., Edited by Stamatoyannopoulos, G., Nienhuis. A.W., 
Saunders, W.B., Philadelphia, 1987, 127. 
 
36. Wyatt, D.M., Berry, C., FEBS Lett. 2002, 513 (2–3), 159. 
 
37. Rosenthal, P.J., Nelson, R.G., Mol. Biochem. Parasitol. 1992, 51 (1), 143. 
 
38. Sijwali, P.S., Shenai, B.R., Gut, J., Singh, A., Rosenthal, P.J., Biochem. J. 2001, 360 (2), 
481. 
 
39. Shenai, B.R., Sijwali, P.S., Singh, A., Rosenthal, P.J., J. Biol. Chem. 2000, 275 29000. 
 
40. Shenai, B.R., Rosenthal, P.J., Mol. Biochem. Parasitol. 2002, 122 (1), 99. 
 
41. Eggleson, K.K., Duffin, K.L., Goldberg, D.E.,  J. Biol. Chem. 1999, 274, 32411. 
 
42. Gluzman, I.Y., Francis, S.E., Oksman, A., Smith, C.E., Duffin, K.L., Goldberg, D.E., J. 
Clin. Invest. 1994, 93 (4), 1602. 
 
43. Fitch, C., Chevli, R., Kanjananggulpan, P., Dutta, P., Chevli, K., Chou, A., Blood. 1983, 
62 (6), 1165. 
 
44. Becker, K., Tilley, L., Vennerstrom, J.L., Roberts, D., Rogerson, S., Ginsburg, H., Int. J. 
Parasitol. 2004, 34 (2), 163. 
 
45. Har-el, R., Marva, M., Chevion, M., Golenser, J., Free Radical Res. 1993, 18 (5), 279. 
 
46. Lancisi, G.M., in ‘De Noxiis Paludum Effluvius Eorumque Remediis’, ed. Salvioni, J. 
M., Rome, 1717. 
 
47. Golgi, C., Representation photographique du development des parasites de 
l’infection paldeene, Verhandldes X Internat. Med. Cong. Berlin Bd II abth III.200, 1890. 
 
48. Weissbuch, I., Leiserowitz, L., Chem. Rev. 2008, 108, 4899. 
 
49. Chen, M.M., Shi, L., Sullivan Jr, D.J., Mol. Biochem. Parasitol. 2001, 113, 1. 
 
50. Noland, G.S., Briones, N., Sullivan Jr, D.J., Mol. Biochem. Parasitol. 2003, 130, 91. 
 
79 
 
51. Pagola, S., Stephens, P.W., Bohle, D.S., Kosar, A.D., Madsen, S.K., Nature 2000, 404 
(6775), 307. 
 
52. Pasternack, R.F., Munda, B., Bickford, A., Gibbs, E.J., Scolaro, L.M., J. Inorg. Biochem. 
2010, 104 (10), 1119. Epub 2010/07/30. 
 
53. Klonis, N., Dilanian, R., Hanssen, E., Darmanin, C., Streltsov, V., Deed, S., Quiney, H., 
Tilley, L., Biochemistry 2010, 49 (31), 6804. 
 
54. Slater, A.F., Swiggard, W.J., Orton, B.R., Flitter, W.D., Goldberg, D.E., Cerami, A., 
Henderson, G.B., Proc. Natl. Acad. Sci. U. S. A. 1991, 88 (2), 325. 
 
55. Bohle, D.S., Debrunner, P., Jordan, P.A., Madsen, S.K., Schulz, C.E., J. Am. Chem. Soc. 
1998, 120 (32), 8255. 
 
56. Bohle, D.S., Dinnebier, R.E., Madsen, S.K., Stephens, P.W., J. Biol. Chem. 1997, 272, 
713. 
 
57. Slater, A. F. G., Cerami, A., Nature 1992, 355, 167. 
 
58. Dorn, A., Stoffel, R., Matile, H., Bubendorf, A., Ridley, R.G., Nature 1995, 374 (6519), 
269. 
 
59. Bendrat, K., Berger, B.J., Cerami, A., Nature 1995, 378 (6553), 138. 
 
60. Goldberg, D.E., Slater, A.F., Cerami, A., Henderson, G.B., Proc. Natl. Acad. Sci. 1990, 
87 (8), 2931. 
 
61. Solomonov, I., Osipova, M., Feldman, Y., Baehtz, C., Kjaer, K., Robinson, I.K., 
Webster, G.T., McNaughton, D., Wood, B.R., Weissbuch, E., Leiserowitz, L., J. Am. Chem. 
Soc. 2007, 129, (9), 2615. 
 
62. Trager, W., Trends Parasitol. 2003, 19 (9), 388. 
 
63. Dorn, A., Vippagunta, S.R., Matile, H., Bubendorf, A., Vennerstron, J.L., Ridley, R. G., 
Biochem. Pharmacol. 1998, 55 (6), 737. 
 
64. Egan, T.J., Mavuso, W. W., Ncokazi, K. K., Biochemistry 2001, 40 (1), 204. Epub 
2001/01/05. 
 
65. Egan, T. F., Tshivhase, M. G., Dalton Trans. 2006 42, 
5024. 
 
80 
 
66. Stiebler, R., Hoang, A. N., Egan, T. J., Wright, D. W., Oliveira, M. F., PLoS One 2010, 5 
(9), e12694. 
 
67. Blauer, G., Akkawi, M., Arch. Biochem. Biophys. 2002, 398 (1), 7. 
 
68. Huy, N. T., Maeda, A., Uyen, D. T., Trang, D. T. X., Sasai, M., Shiono, T., Oida, T., 
Harada, S., Kamei, K., Acta Trop. 2007, 101 (2), 130. 
 
69. Jackson, K. E., Klonis, N., Ferguson, D. J. P., Adisa, A., Dogovski, C., Tilley, L., Mol. 
Microbiol. 2004, 54 (1), 109. 
 
70. Pisciotta, J., Coppens, I., Tripathi, A., Scholl, P., Shuman, J., Bajad, S., Shulaev, V., 
Sullivan Jr, D. J., Biochem. J. 2007, 402 (Pt 1), 197. 
 
71. Papalexis, V., Siomos, M. -A., Campanale, N., Guo, X. –G., Kocak, G., Foley, M., Tilley, 
L., Mol. Biochem. Parasitol. 2001, 115 (1), 77. 
 
72. Hoang, A. N., Sandlin, R. D., Omar, A., Egan, T. J., Wright, D. W., Biochemistry 2010, 
49 (47), 10107. 
 
73. Hoang, A. N., Ncokazi, K. K., de Villiers, K. A., Wright, D. W., Egan, T. J., Dalton Trans. 
2010, 39 (5), 1235. 
 
74. Egan, T. J., Combrinck, J. M., Egan, J., Hearne, G. R., Marques, H. M., Ntenteni, S., 
Sewell, B. T., Smith, P. J., Taylor, D., van Schalkwyk, D. A., Walden, J. C., Biochem J. 2002, 
365 (Pt 2), 343. 
 
75. Egan, T. J., Chen, J. Y. –J., de Villiers, K. A., Mabotha, T. E.,  Naidoo, K. J., Ncokazi, K. 
K., et al. FEBS Lett. 2006, 580, 5105. 
 
76. Downie, M. J., Kirk, K., Mamoun, C. B., Eukaryot. Cell. 2008, 7 (8), 1231. 
 
77. Ben Mamoun, C., Prigge, S. T., Vial, H., Drug Dev. Res. 2010, 71 (1), 44. 
 
78. Woodrow, C. J., Krishna, S., eds, ‘Molecular Approaches to Malaria: Glycolysis in 
Asexual-Stage Parasites’, 1st edition, American Society for Microbiology, Washington 
D.C., 2005. 
 
79. Sato, S., Clough, B., Coates, L., Wilson, R. J. M., Protist 2004, 155 (1), 117. 
 
80. Bergman, G. J., Sci. Edu. 1948, 32 (2), 93. 
 
81. Warhurst, D., Craig, J., Adagu, I., Meyer, D., Lee, S., Malar. J. 2003, 2 (1), 26. 
 
81 
 
82. Krogstad, D., Gluzman, I., Kyle, D., Oduola, A., Martin, S., Milhous, W., Schlesinger, P. 
H., Science 1987, 238 (4831), 1283. 
 
83. Asher, C., de Villiers, K. A., Egan, T. J., Inorg. Chem. 2009, 48 (16), 7994. 
 
84. de Villiers, K. A., Kaschula, C. H., Egan, T. J., Marques, H. M., J. Biol. Inorg. Chem. 
2007, 12 (1), 101. 
 
85. Krogstad, D. J., Schlesinger, P. H., Biochem. Pharmacol. 1986, 35, 547. 
 
86. Moreau, S., Perly, B., Biguet, J., Biochimie 1982, 64 (11–12), 1015. Epub 1982/11/01. 
 
8 . O’Neill, P. M., Willock, D. J., Hawley, S. R., Bray, P. G., Storr, R. C., Ward, S. A., Park, 
B. K., J. Med. Chem. 1997, 40 (4), 437. 
 
88. Cohen, S. N., Phifer, K. O., Yielding, K. L., Nature 1964, 202, 805. 
 
89. Chou, A. D., Chevli, R., Fitch, C. D., Biochemistry 1980, 19 (8), 1543. 
 
90. Egan, T. J., Ncokazia, K. K., J. Inorg. Biochem. 2004, 98 (1), 144. 
 
91. Egan, T. J., Mavuso, W. W., Ross, D. C., Marques, H. M., J. Inorg. Biochem. 1997, 68 
(2), 137. 
 
92. Egan, T. J., J. Inorg. Biochem. 2006, 100 (5–6), 916. 
 
93. Buller, R., Peterson, M. L., Almarsson, O., Leiserwitz, L., Cryst. Growth Des. 2002, 2 
(6), 553. 
 
94. Sullivan, D. J., Gluzman, I. Y., Russell, D. G., Goldberg, D. E., Proc. Natl. Acad. Sci. U. S. 
A. 1996, 93 (21), 11865. 
 
95. Dorn, A., Vippagunta, S. R., Matile, H., Jaquet, C., Vennerstrom, J. L., Ridley, R. G., 
Biochem. Pharmacol. 1998, 55 (6), 727. Epub 1998/05/20. 
 
96. de Villiers, K. A., Marques, H. M., Egan, T. J., J. Inorg. Biochem. 2008, 102 (8), 1660. 
 
97. Ignatushchenko, M. A., Winter, R. W., Riscoe, M., Am. J. Trop. Med. Hyg. 2000, 62 
(1), 77. 
 
98. Winter, R. W., Cornell, K. A., Johnson, L. L., Ignatushchenko, M., Hinrichs, D. J., 
Riscoe, M. K., Antimicrob. Agents Chemother. 1996, 40 (6), 1408. 
 
82 
 
99. Ignatushchenko, M. V., Winter, R. W., Bachinger, H. P., Hinrichs, D. J., Riscoe, M. K., 
FEBS Lett. 1997, 409 (1), 67. 
 
100. Kelly, J. X., Winter, R., Riscoe, M., Peyton, D. H., J. Inorg. Biochem. 2001, 86 (2 -3), 
617. 
 
101. Kelly, J. X., Winter, R., Peyton, D. H., Hinrichs, D. J., Riscoe, M., Antimicrob. Agents 
Chemother. 2002, 46 (1), 144. 
 
102. Group, C. C. R., J. Tradit. Chin. Med. 1982, 2, 3. 
 
103. Meshnick, S. R., Taylor, T. E., Kamchonwongpaisan, S., Microbiol. Rev. 1996, 60, 
301. 
 
104. Posner, G. H., Oh, C. H., Wang, D., Gerena, L., Milhous, W. K., Meshnick, S. R., 
Asawamahasadka, W., J. Med. Chem., 1994, 37, 1256. 
 
105. Kamchonwongpaisan, S., Meshnick, S. R., Gen. Pharmacol. 1996, 27, 587. 
 
106. Meshnick, S., Yang, Y., Lima, V., Kuypers, F., Kamchonwongpaisan, S., Yuthavong, Y., 
Antimicrob. Agents Chemother. 1993, 37 (5), 1108. 
 
107. Zhang, F., Gosser Jr, D. K., Meshnick, R., Biochem. Pharmacol. 1992, 43, 1805. 
 
108. Bhisutthibhan, J., Pan, X. Q., Hossler, P. A., Walker, D. J., Yowell, C. A., Carlton, J., 
Dame, J. B., Meshnick, S. R., J. Biol. Chem. 1998, 273, 16192. 
 
109. Bhisutthibhan, J., Meshnick, S. R., Antimicrob. Agents Chemother. 2001, 45, 2397. 
 
110. Ellis, D. S., Li, Z. L., Gu, H. M., Peters, W., Robinson, B. L., Tovey, G., Warhurst, D. C., 
Ann. Trop. Med. Parasitol. 1985, 79, 367. 
 
111. Jiang, J. B., Jacobs, G., Liang, D. S., Aikawa, M., Am. J. Trop. Med. Hyg. 1985, 34, 
424. 
 
112. Maeno, Y. T., Toyoshima, T., Fujioka, H., Ito, Y., Meshnick, S. R., Benakis, A., 
Milhous, W. K., Aikawa, M., Am. J. Trop. Med. Hyg. 1993, 49, 485. 
 
113. Johnson, J. D., Dennull, R. A., Gerena, L., Lopez-Sanchez, M., Roncal, N. E., Waters, 
N. C., Antimicrobial. Agents Chemother. 2007, 51 (6), 1926. 
 
114. Lucumi, E., Darling, C., Jo, H., Napper, A. D., Chandramohanadas, R., Fisher, N., 
Shone, A. E., Jing, J., Ward, S. A., Biagini, G. A., DeGrado, W. F., Diamond, S. L., 
Greenbaum, D. C., Antimicrobial. Agents Chemother. 2010, 54 (9), 3597. 
83 
 
 
115. Baniecki, M. L., Wirth, D. F., Clardy, J., Antimicrobial. Agents Chemother. 2007, 51 
(2), 716. 
 
116. Corbett, Y., Herrera, L., Gonzalez, J., Cubilla, L., Capson, T. L., Coley, P. D., Kursar, T. 
A., Romero, L. I., Ortega-Barria, E., Am. J. Trop. Med. Hyg. 2004, 70, 119. 
 
117. Rush, M. A., Baniecki, M. L., Mazitschek, R., Cortese, J. F., Wiegand, R., Clardy, J., 
Wirth, D. F., Antimicrobial. Agents Chemother. 2009, 53 (6), 2564. 
 
118. Kurosawa, Y., Dorn, A., Kitsuji-Shirane, M., Shimada, H., Satoh, T., Matile, H., 
Hofheinz, W., Masciadri, R., Kansy, M., Ridley, R. G., Antimicrobial. Agents Chemother. 
2000, 44 (10), 2638. 
 
119. Koehn, F. E., Carter, G. T., Nature Reviews Drug Discovery 2005, 4, 206-220. 
 
120. Bérdy, J., J. Antibiot. 2005, 58, 1-26. 
 
121. Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., Potts, B. C., 
Bioorganic and Medicinal Chemistry 2009, 17, 2175-2180. 
 
122. Carter, M., Phelan, V., Sandlin, R., Bachmann, B., Wright, D., Combinatorial 
Chemistry & High Throughput Screening 2010, 13, 285-292. 
 
123. Mann, J., Natural Product Reports 2001, 18, 417-430. 
 
124. Lam, K. S., Current Opinion In Microbiology 2006, 9, 245-251. 
 
125. Chabala, J. C., Mrozik, H., Tolman, R. L., Eskola, P., Lusi, A., Peterson, L. H., Woods, 
M. F., Fisher, M. H., Campbell, W. C., Journal of Medicinal Chemistry 1980, 23, 1134-
1136. 
 
126. Fowler, A., Swift, D., Longman, E., Acornley, A., Hemsley, P., Murray, D., Unitt, J., 
Dale, I., Sullivan, E., Coldwell, M., Analytical Chemistry 2002, 308, 223-231. 
 
127. Dixon, R.A, Ferreira, D., Phytochemistry 2002, 60, 205-211. 
128. Cunha-Rodrigues, M., Portugal, S., Prudencio, M., Goncalves, L. A., Casalou, C., 
Buger, D., Sauerwein, R., Haas, W., Mota, M. M., PLoS ONE 2008, 3 (7), e2732. 
129. Gazarini, M. L., Garcia, C. R. S., Braz. J. Med. Biol. Res. 2003, 36, 1465-1469. 
 
84 
 
 
